Status:
COMPLETED
Effect of Inhaled Albuterol in Pulmonary Hypertension
Lead Sponsor:
University of Miami
Conditions:
Pulmonary Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of the present pilot study is to test the hypothesis that in patients with group 1 pulmonary arterial hypertension (PAH) who are on regular oral pulmonary vasodilator therapy, inhaled albu...
Eligibility Criteria
Inclusion
- A Mean Pulmonary Artery Pressure \>25mmHg, Pulmonary Vascular Resistance \>3 wood/units and pulmonary arterial wedge pressure \<15mmHg, as documented by right heart catheterization within the last 3 years
- Regular use of oral pulmonary vasodilators
Exclusion
- Presence of chronic respiratory disease (as documented by prior lung imaging and pulmonary function tests), cardiovascular disease (as documented by prior echocardiography and/or left heart catheterization), thromboembolic PAH (as documented by pulmonary angiography)
- women of childbearing potential who do not use accepted birth- control measures
- pregnant and breast-feeding women
- respiratory infection within 4 weeks of testing
- A systemic systolic arterial BP\> 150 and/or diastolic arterial BP\>100 on the experiment day
- A resting O2 saturation of \< 90%
- Current smoking
- BMI \>35 kg/m2 and/or a diagnosis of obstructive sleep apnea
- Use of inhaled or intravenous pulmonary vasodilators
Key Trial Info
Start Date :
October 5 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 2 2020
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT03270332
Start Date
October 5 2017
End Date
July 2 2020
Last Update
August 30 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Miami
Miami, Florida, United States, 33136